The predictive value of treatment response using FDG PET performed on day 21 of chemoradiotherapy in patients with oesophageal squamous cell carcinoma. A prospective, multicentre study (RTEP3)

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 9, 2013, Pages 1345-1355

  Palie, Odré ^a   Michel, Pierre ^a   Ménard, Jean François ^a   Rousseau, Caroline ^b   Rio, Emmanuel ^b   Bridji, Boumédiene ^b   Benyoucef, Ahmed ^c   Meyer, Marc Etienne ^d   Jalali, Khadija ^d   Bardet, Stéphane ^e   M'Vondo, Che Mabubu ^e   Olivier, Pierre ^f   Faure, Guillaume ^g   Itti, Emmanuel ^h   Diana, Christian ^h   Houzard, Claire ⁱ   Mornex, Françoise ⁱ   Di Fiore, Frederic ^a   Vera, Pierre ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b Institut de Cancerologie de l'Quest Rene Gauducheau   (France)

^c Henri Becquerel Cancer Center   (France)

^d AMIENS UNIVERSITY HOSPITAL   (France)

^e Francois Baclesse Cancer Institute   (France)

^f UNIVERSITY HOSPITAL OF NANCY   (France)

^g Hôpital Belle Isle   (France)

^h HENRI MONDOR HOSPITAL   (France)

ⁱ HOSPICES CIVILS DE LYON   (France)

Author keywords

Chemoradiotherapy; Fluoro deoxy d glucose; Oesophageal cancer; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CHEMORADIOTHERAPY; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GLYCOLYSIS; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 84881637328     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2450-7     Document Type: Article

References (42)

1. Keighley MR. Gastrointestinal cancers in Europe. Aliment Pharmacol Ther. 2003;18 Suppl 3:7-30. PubMed PMID: 14531737. Epub 2003/10/09. eng.
2. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349(23):2241-52. PubMed PMID: 14657432. Epub 2003/12/06. eng.
3. Courrech Staal EF, Aleman BM, Boot H, van Velthuysen ML, van Tinteren H, van Sandick JW. Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer. Br J Surg. 2010;97(10):1482-96. PubMed PMID: 20645400. Epub 2010/07/21. eng.
4. Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25(10):1160-8. PubMed PMID: 17401004. Epub 2007/04/03. eng.
5. Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23(10):2310-7. PubMed PMID: 15800321. Epub 2005/04/01. eng.
6. Jones DR, Parker Jr LA, Detterbeck FC, Egan TM. Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. Cancer. 1999;85(5):1026-32. PubMed PMID: 10091784. Epub 1999/03/26. eng.
7. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson Jr JA, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999;281(17):1623-7. PubMed PMID: 10235156. Epub 1999/05/11. eng.
8. Di Fiore F, Blondin V, Hitzel A, et al. 18F-Fluorodeoxyglucose-positron emission tomography after definitive chemoradiotherapy in patients with esophageal cancer. Dig Liver Dis. 2012;44(10):875-9.
9. Krause BJ, Herrmann K, Wieder H, zum Buschenfelde CM. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer. J Nucl Med. 2009;50 Suppl 1:89S-96S. PubMed PMID: 19380406. Epub 2009/04/22. eng.
10. Ben-Haim S, Ell P. 18F-FDG PET and PET/CT in the evaluation of cancer treatment response. J Nucl Med. 2009;50(1):88-99. PubMed PMID: 19139187. Epub 2009/01/14. eng.
11. Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med. 2005;46(6):983-95. PubMed PMID: 15937310. Epub 2005/06/07. eng.
12. Barber TW, Duong CP, Leong T, Bressel M, Drummond EG, Hicks RJ. 18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data. J Nucl Med. 2012;53(6):864-71. PubMed PMID: 22582047. Epub 2012/05/15. eng.
13. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571-8. PubMed PMID: 17242397. Epub 2007/01/24. eng.
14. Hicks RJ. Role of 18F-FDG PET in assessment of response in non-small cell lung cancer. J Nucl Med. 2009;50 Suppl 1:31S-42S. PubMed PMID: 19380411. Epub 2009/04/22. eng.
15. Edet-Sanson A, Dubray B, Doyeux K, Back A, Hapdey S, Modzelewski R, et al. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC). Radiother Oncol. 2012;102(2):251-7. PubMed PMID: 21885145. Epub 2011/09/03. eng.
16. Gupta T, Jain S, Agarwal JP, Rangarajan V, Purandare N, Ghosh-Laskar S, et al. Diagnostic performance of response assessment FDG-PET/CT in patients with head and neck squamous cell carcinoma treated with high-precision definitive (chemo)radiation. Radiother Oncol. 2010;97(2):194-9. PubMed PMID: 20627432. Epub 2010/07/16. eng.
17. Omloo JM, van Heijl M, Hoekstra OS, van Berge Henegouwen MI, van Lanschot JJ, Sloof GW. FDG-PET parameters as prognostic factor in esophageal cancer patients: a review. Ann Surg Oncol. 2011;18(12):3338-52. PubMed PMID: 21537872. Pubmed Central PMCID: 3192273. Epub 2011/05/04. eng.
18. Kwee RM. Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of 18F FDG PET: a systematic review. Radiology. 2010;254(3):707-17. PubMed PMID: 20177086. Epub 2010/02/24. eng.
19. Vermandel M, Fin L, Hapdey S, Bol A, Betrouni N, Daouk J, et al. An easy-to-use phantom and protocol for weekly PET quality assessment: a multicenter study. Med Phys. 2008;35(9):3922-34.
20. Lin C, Itti E, Haioun C, Petegnief Y, Luciani A, Dupuis J, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. 2007;48(10):1626-32.
21. Boellaard R, Oyen WJ, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging. 2008;35(12):2320-33. PubMed PMID: 18704407. Epub 2008/08/16. eng.
22. Boellaard R. Need for standardization of 18F-FDG PET/CT for treatment response assessments. J Nucl Med. 2011;52 Suppl 2:93S-100S. PubMed PMID: 22144561. Epub 2011/12/22. eng.
23. Safar V, Dupuis J, Itti E, Jardin F, Fruchart C, Bardet S, et al. Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. J Clin Oncol. 2012;30(2):184-90.
24. Vauclin S, Doyeux K, Hapdey S, Edet-Sanson A, Vera P, Gardin I. Development of a generic thresholding algorithm for the delineation of 18FDG-PET-positive tissue: application to the comparison of three thresholding models. Phys Med Biol. 2009;54(22):6901-16. PubMed PMID: 19864698. Epub 2009/10/30. eng.
25. Erdi YE, Mawlawi O, Larson SM, Imbriaco M, Yeung H, Finn R, et al. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer. 1997;80(12 Suppl):2505-9. PubMed PMID: 9406703. Epub 1997/12/24. eng.
26. Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron imaging. 1999;2(3):159-71. PubMed PMID: 14516540. Epub 2003/10/01. Eng.
27. Roedl JB, Colen RR, Holalkere NS, Fischman AJ, Choi NC, Blake MA. Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation. Radiother Oncol. 2008;89(3):278-86. PubMed PMID: 18701180. Epub 2008/08/15. eng.
28. Tougeron D, Di Fiore F, Hamidou H, Rigal O, Paillot B, Michel P. Response to definitive chemoradiotherapy and survival in patients with an oesophageal adenocarcinoma versus squamous cell carcinoma: a matched-pair analysis. Oncology. 2007;73(5-6):328-34. PubMed PMID: 18497505. Epub 2008/05/24. eng.
29. Geets X, Daisne JF, Tomsej M, Duprez T, Lonneux M, Gregoire V. Impact of the type of imaging modality on target volumes delineation and dose distribution in pharyngo-laryngeal squamous cell carcinoma: comparison between pre- and per-treatment studies. Radiother Oncol. 2006;78(3):291-7. PubMed PMID: 16499982. Epub 2006/02/28. eng.
30. Bruzzi JF, Swisher SG, Truong MT, Munden RF, Hofstetter WL, Macapinlac HA, et al. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer. 2007;109(1):125-34. PubMed PMID: 17146785. Epub 2006/12/06. eng.
31. Song SY, Kim JH, Ryu JS, Lee GH, Kim SB, Park SI, et al. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. Int J Radiat Oncol Biol Phys. 2005;63(4):1053-9.
32. Brink I, Hentschel M, Bley TA, Walch A, Mix M, Kleimaier M, et al. Effects of neoadjuvant radio-chemotherapy on 18F-FDG-PET in esophageal carcinoma. Eur J Surg Oncol. 2004;30(5):544-50. PubMed PMID: 15135484. Epub 2004/05/12. eng.
33. Arslan N, Miller TR, Dehdashti F, Battafarano RJ, Siegel BA. Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-D- glucose with positron emission tomography in patients with esophageal cancer. Mol Imaging Biol. 2002;4(4):301-10. PubMed PMID: 14537121. Epub 2003/10/11. eng.
34. Monjazeb AM, Riedlinger G, Aklilu M, Geisinger KR, Mishra G, Isom S, et al. Outcomes of patients with esophageal cancer staged with [18F] fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection? J Clin Oncol. 2010;28(31):4714-21. PubMed PMID: 20876421. Pubmed Central PMCID: 3020701. Epub 2010/09/30. eng.
35. Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2006;24(29):4692-8. PubMed PMID: 16966684. Epub 2006/09/13. eng.
36. Wieder HA, Brucher BL, Zimmermann F, Becker K, Lordick F, Beer A, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol. 2004;22(5):900-8. PubMed PMID: 14990646. Epub 2004/03/03. eng.
37. Westerterp M, Omloo JM, Sloof GW, Hulshof MC, Hoekstra OS, Crezee H, et al. Monitoring of response to pre-operative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET. Intern J Hyperther. 2006;22(2):149-60. PubMed PMID: 16754598. Epub 2006/06/07. eng.
38. Kroep JR, Van Groeningen CJ, Cuesta MA, Craanen ME, Hoekstra OS, Comans EF, et al. Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods. Mol Imaging Biol. 2003;5(5):337-46. PubMed PMID: 14630513. Epub 2003/11/25. eng.
39. Fukunaga T, Okazumi S, Koide Y, Isono K, Imazeki K. Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET. J Nucl Med. 1998;39(6):1002-7. PubMed PMID: 9627333. Epub 1998/06/17. eng.
40. Kato H, Fukuchi M, Miyazaki T, Nakajima M, Tanaka N, Inose T, et al. Prediction of response to definitive chemoradiotherapy in esophageal cancer using positron emission tomography. Anticancer Res. 2007;27(4C):2627-33. PubMed PMID: 17695425. Epub 2007/08/19. eng.
41. Makino T, Miyata H, Yamasaki M, Fujiwara Y, Takiguchi S, Nakajima K, et al. Utility of response evaluation to neo-adjuvant chemotherapy by (18)F-fluorodeoxyglucose-positron emission tomography in locally advanced esophageal squamous cell carcinoma. Surgery. 2010;148(5):908-18. PubMed PMID: 20378140. Epub 2010/04/10. eng.
42. Hatt M, Visvikis D, Albarghach NM, Tixier F, Pradier O, Cheze-le Rest C. Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology. Eur J Nucl Med Mol Imaging. 2011;38(7):1191-202. PubMed PMID: 21365252. Epub 2011/03/03. eng.